Channelchek - Looking for the next apple? This is the orchard.

ZOMDF

$0.11

(-1.53%)

FLWS

$4.29

(-4.03%)

ACCO

$3.83

(-0.26%)

ARLP

$23.59

(0.7%)

AUIAF

$0.12

(-10.73%)

AZZ

$108.12

(0.18%)

BTBT

$2.23

(10.4%)

BTM

$1.37

(5.56%)

CVKD

$7.08

(-3.93%)

LCE:CA

$0.29

(1.72%)

COCP

$1.02

(2%)

CDRO

$7.79

(3.45%)

CVGI

$1.52

(-0.65%)

LODE

$3.72

(6.59%)

CMTL

$3.18

(3.25%)

CNDT

$2.02

(-0.74%)

CXW

$19.26

(-1.83%)

CMLS

$0.08

(-0.54%)

DRCT

$0.07

(6.18%)

DLHC

$5.61

(0.9%)

SSP

$4.74

(-1.04%)

ELDN

$1.64

(4.14%)

EVC

$3.21

(1.42%)

EDRY

$13.06

(-1.09%)

ESEA

$55.49

(2.65%)

FAT

$0.44

(-0.32%)

RAIL

$9.18

(-2.75%)

GDEV

$17.03

(-4.75%)

GOVX

$0.15

(-39.36%)

GOCO

$2.47

(-4.36%)

GHM

$61.92

(1.78%)

GLDD

$13.56

(0.89%)

GYRE

$7.75

(-1.27%)

HMENF

$1.43

(-0.38%)

III

$5.97

(-0.06%)

IPOOF

$8.85

(0.23%)

KELYA

$8.97

(-1.1%)

KTOS

$74.67

(4.58%)

LUCK

$9.05

(0.17%)

MAIA

$1.25

(4.17%)

MGROF

$0.56

(10%)

NTRB

$4.63

(2.21%)

OCGN

$1.43

(-0.69%)

PERF

$1.8

(1.69%)

QMCI

$0.15

(0%)

RGP

$5.2

(-1.24%)

SGA

$11.43

(0.7%)

SHWZ

(0%)

SHIP

$9.49

(-0.94%)

SLQT

$1.35

(-2.88%)

SKYX

$2.21

(7%)

SNAL

$0.88

(-1.75%)

GEO

$16.16

(-2.24%)

ODP

(0%)

TNXP

$17.35

(-4.72%)

TSQ

$5.33

(1.12%)

TZOO

$7.25

(-2.67%)

UNCY

$5.49

(1.57%)

VVX

$53.6

(0.69%)

VNCE

$4.02

(13.08%)

XELB

$1.22

(9.91%)

ZOMDF

$0.11

(-1.53%)

FLWS

$4.29

(-4.03%)

channelchek-in

‌

12/19/2025

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Leadership in Rare Diseases

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced it has entered into a definitive agreement to acquire Amicus Therapeutics (Nasdaq: FOLD) in an all-cash transaction valued at approximately $4.8 billion. Under the terms of the deal, BioMarin will acquire Amicus for $14.50 per share, representing a significant premium to Amicus’ recent trading levels. The transaction is expected to close in the second quarter of 2026, subject to regulatory approvals and Amicus shareholder approval.

3 min read